Forget Aurora Cannabis (TSX:ACB): This Could Be a Much Safer Pot Stock to Invest in

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) has achieved significant sales growth recently, but that doesn’t mean that the stock is the best option for cannabis investors today.

| More on:
Road signs rerouting traffic

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aurora Cannabis (TSX:ACB)(NYSE:ACB) may be one of the top stocks in the industry, but that doesn’t mean that it’s the best investment that cannabis investors can make today. Although the company has been showing strong sales growth in recent quarters, it has also incurred losses of around $400 million over just the past two quarters. Now more than ever, cannabis investors are paying close attention to not just sales numbers but profits as well.

Pot stocks have been struggling lately, and although Aurora is up year to date, since February the stock has been down. In the past few months, we’ve seen a lot of bearish activity surrounding the industry. Cannabis investors are demanding more substance from companies before investing their hard-earned dollars in them, especially given the recent CannTrust scandal underlining just how much risk there is in the industry.

That’s where a company like OrganiGram Holdings (TSXV:OGI)(NASDAQ:OGI) could have a lot of value with investors. Unlike many of its peers, its financials have been very strong. The company is coming off a record quarter where its sales hit $25 million, showing terrific growth of more than 600% from the prior year. And had it not been for the company incurring fair-value losses of $12.5 million, it could have easily ended up with a profit as its net loss for the quarter was $10.2 million.

What’s encouraging is the company’s ability to control costs. Despite the significant increase in sales, expenses didn’t outpace revenue growth and left a lot of room for incremental revenue to flow through to the company’s bottom line. That’s what investors should come to expect from well-managed companies, that more sales should lead to a stronger bottom line, not the opposite. Unfortunately, that’s what we’ve come to expect with many marijuana companies, as excessive spending has often sent their financials deep into the red. And that’s likely a key reason why Bruce Linton was let go from his position at Canopy Growth, because the company’s financials had gone from bad to worse.

Another positive for OrganiGram is that it hasn’t been burning through a lot of cash, and when it has been doing so, it’s been to help fund its inventory. Over the past nine months, the company has spent more than $49 million on inventory. Without such a hefty expenditure, the company’s cash flow from operations would have been positive during that time. And without excessive cash burn, a company’s need to raise capital lessens, resulting in less debt and equity issues.

Bottom line

Cannabis investors are on high alert knowing that the industry is definitely a lot more fragile today than it was a month ago. However, there are often signs of a good company versus a bad one, and being able to control costs is certainly one of them. That’s what makes OrganiGram an appealing option for investors today. With strong numbers and the potential for the company to produce a positive net income in future quarters, it could find itself in demand, as investors look for safer investments in the cannabis industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »